

New Jersey Institute of Radiology, PC
Advanced Medical Imaging Center
630 Broad Street, Carlstadt, NJ 07072
Tel. 201-372-1020, 888-372-1020, Fax 201-372-1028
WWW.NJIRONLINE.COM

August 20th, 2008

Br. 1

2008 AUG 27 PM 1:03

RECEIVED
REGION 1

Sandra Gabreil
Senior Health Physicist
Division of Nuclear Materials Safety
NRC, Region 1
475 Allendale Raod
King of Prussia, PA 19406

03037113


Ref: New Jersey Institute of Radiology : Application for amending NRC license # 29-31119-01.

Dear Ms. Gabriel

This application is submitted to add Shelley Ann Quarless, D.O, Ph.D., authorized user to NRC license # 29-31119-01 for diagnostic and radiotherapy under 35.100, 35.200, and 35.300

Dr. Quarless will be providing services as a nuclear medicine physician at this facility. Dr. Quarless is a qualified nuclear medicine physician obtained her residency from John Hopkins University Hospital, Baltimore, MD. She is a licensed physician in New Jersey and board certified by the American Board of Nuclear Medicine (2001).

Dr. Quarless has worked as staff nuclear medicine physician and assistant chief of nuclear medicine from 2002-2005 at Tripler Army Hospital, Honolulu, Hawaii. She was authorized user under the hospital broad license performing diagnostic and therapeutic nuclear medicine studies under 35.100, 35.200 and 35.300. (copy of license is attached). Attached copies of Dr. Quarless credentials, licenses and board certification.


Adel Mustafa, Ph.D., DABR
Director

142741

NRC FORM 313 (10-2005) 10 CFR 30, 32, 33, 34, 35, 36, 39, and 40	U.S. NUCLEAR REGULATORY COMMISSION	APPROVED BY OMB: NO. 3150-0120 Estimated burden per response to comply with this mandatory collection request: 4.4 hours. Submittal of the application is necessary to determine that the applicant is qualified and that adequate procedures exist to protect the public health and safety. Send comments regarding burden estimate to the Records and FOIA/Privacy Services Branch (T-5 F53), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by internet e-mail to infocollects@nrc.gov , and to the Desk Officer, Office of Information and Regulatory Affairs, NEOB-10202, (3150-0120), Office of Management and Budget, Washington, DC 20503. If a means used to impose an information collection does not display a currently valid OMB control number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.	EXPIRES: 10/31/2008
APPLICATION FOR MATERIAL LICENSE			

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

APPLICATION FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH: DIVISION OF INDUSTRIAL AND MEDICAL NUCLEAR SAFETY OFFICE OF NUCLEAR MATERIALS SAFETY AND SAFEGUARDS U.S. NUCLEAR REGULATORY COMMISSION WASHINGTON, DC 20555-0001 ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS: IF YOU ARE LOCATED IN: ALABAMA, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, KENTUCKY, MAINE, MARYLAND, MASSACHUSETTS, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, NORTH CAROLINA, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, VERMONT, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO: LICENSING ASSISTANCE TEAM DIVISION OF NUCLEAR MATERIALS SAFETY U.S. NUCLEAR REGULATORY COMMISSION, REGION I 475 ALLENDALE ROAD KING OF PRUSSIA, PA 19406-1415	IF YOU ARE LOCATED IN: ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO: MATERIALS LICENSING BRANCH U.S. NUCLEAR REGULATORY COMMISSION, REGION III 2443 WARRENVILLE ROAD, SUITE 210 LISLE, IL 60532-4352 ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, HAWAII, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEVADA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, OREGON, PACIFIC TRUST TERRITORIES, SOUTH DAKOTA, TEXAS, UTAH, WASHINGTON, OR WYOMING, SEND APPLICATIONS TO: NUCLEAR MATERIALS LICENSING BRANCH U.S. NUCLEAR REGULATORY COMMISSION, REGION IV 611 RYAN PLAZA DRIVE, SUITE 400 ARLINGTON, TX 76011-4005
---	---

03037113

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTIONS.

1. THIS IS AN APPLICATION FOR (Check appropriate item) <input type="checkbox"/> A. NEW LICENSE <input checked="" type="checkbox"/> B. AMENDMENT TO LICENSE NUMBER <u>29-31119-01</u> <input type="checkbox"/> C. RENEWAL OF LICENSE NUMBER _____	2. NAME AND MAILING ADDRESS OF APPLICANT (Include ZIP code) <i>New Jersey Institute of Radiology</i> <i>630 Broad St.</i> <i>Carlstadt, NJ 07072</i>
---	---

3. ADDRESS WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED <i>New Jersey Institute of Radiology</i> <i>630 Broad St.</i> <i>Carlstadt, NJ 07072</i>	4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION <i>Adel Mustafa, Ph.D.</i> TELEPHONE NUMBER <i>201 372 1020</i>
--	---

SUBMIT ITEMS 5 THROUGH 11 ON 8-1/2 X 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE

5. RADIOACTIVE MATERIAL a. Element and mass number; b. chemical and/or physical form; and c. maximum amount which will be possessed at any one time.	6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.
7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING EXPERIENCE.	8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.
9. FACILITIES AND EQUIPMENT.	10. RADIATION SAFETY PROGRAM.
11. WASTE MANAGEMENT.	12. LICENSE FEES (See 10 CFR 170 and Section 170.31) FEE CATEGORY _____ AMOUNT ENCLOSED \$ _____

13. CERTIFICATION. (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.


THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, 36, 39, AND 40, AND THAT ALL INFORMATION CONTAINED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

CERTIFYING OFFICER - TYPED/PRINTED NAME AND TITLE <i>ADEL MUSTAFA, Ph.D., Director</i>	SIGNATURE 	DATE <i>8/25/08</i>
---	---------------	------------------------

FOR NRC USE ONLY					
TYPE OF FEE	FEE LOG	FEE CATEGORY	AMOUNT RECEIVED	CHECK NUMBER	COMMENTS
			\$		
APPROVED BY				DATE	

SHELLEY A. QUARLESS



EDUCATION:

Premedical
1978 B.S.

Excelsior College, Albany, New York (Biology)

1980 Ph.D.

International College, Los Angeles, California (Molecular Biology)
Thesis Research: Columbia University, New York, New York
Thesis Advisor: Dr. Charles R. Cantor, Ph.D.

Medical

1996 D.O.

Des Moines University-Osteopathic Medical Center, College of Osteopathic Medicine
Des Moines, Iowa

**PERSONAL INFORMATION WAS REMOVED
BY NRC. NO COPY OF THIS INFORMATION
WAS RETAINED BY THE NRC.**

POSTGRADUATE MEDICAL EDUCATION:

07/96-06/97

Resident, Department of Pathology, Rhode Island Hospital, Brown University School of medicine, Providence, Rhode Island

07/97-02/98

Research Fellow, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

03/98-03/99

Intern, Department of Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland

07/99-06/00

Clinical Fellow (PET Imaging), Department of Radiology, Division of Nuclear Medicine, Johns Hopkins Hospital, Baltimore, Maryland

07/00-06/02

Resident, Department of Radiology, Division of Nuclear Medicine, Johns Hopkins Hospital, Baltimore, Maryland

HOSPITAL APPOINTMENTS:

12/02-11/05

Staff Physician and Assistant Chief of Nuclear Medicine, Dept. of Radiology, Tripler Army Medical Center, Honolulu, Hawaii
-CAPT U.S. Army Medical Corp 09/02-10/03
-MAJ U.S. Army Medical Corp 10/03-11/05

CERTIFICATION:

United States Medical Licensing Examination (USMLE)
Step I - September, 1994 - Passed
Step II - March, 1996 - Passed
Step III - May, 1997 - Passed

Diplomate, American Board of Nuclear Medicine - September 8, 2001 - # 07192

MEDICAL LICENSE: Massachusetts: #155420, full-inactive (issued September 24, 1997)
New Jersey: #25MB07992700, full-active (issued October 5, 2005)

AWARDS:

2005

The Army Commendation Medal, for meritorious service as Assistant Chief, Nuclear Medicine Service Dept. of Radiology, Tripler Army Medical Center, Hawaii

Shelley A. Quarless

Publications:

Quarless SA., Cantor CR. Analysis of RNA structure by ultraviolet crosslinking and denaturation gel electrophoresis. *Anal. Biochem.* 1985; 147:296-300

Quarless SA. Coupled endo-exodeoxyribonuclease activity from HeLa cell nuclei interacts with specific regions of the SV40 mini chromosome. *Biochem. Biophys. Res. Commun.* 1985; 126:805-11

Quarless SA. Coupled endo-exodeoxyribonuclease activity from HeLa cell nuclei can function in an excision repair mode in vitro. *Biochem. Biophys. Res. Commun.* 1985; 126:812-17

Quarless SA. Identification of an ionic strength sensitive nuclear protein kinase activity from the cervical carcinoma HeLa. *Biochem. Biophys. Res. Commun.* 1985; 133:981-87

Quarless SA. Identification of a deoxyribonuclease activity in the nuclei of the cervical carcinoma HeLa. *Cancer Biochem. Biophys* 1986; 8:211-20

Quarless SA., Heinrich G. The use of complementary RNA and S1 nuclease for the detection and quantitation of low abundance m RNA transcripts. *BioTechniques* 1986; 4:344-38

Quarless SA., Heinrich G. Regulation of nerve growth factor gene expression in primary brain monolayer cultures: Effect of dibutyryl cyclic AMP and sodium butyrate. *Brain Res.* 1987; 2:235-42

Quarless SA. Chloriquine enhances the cytotoxicity of cis-diaminedichloroplatinum II. *Cancer Biochem. Biophys.* 1988; 10:11-15

Quarless SA., Lam DMK. The expression of high molecular weight astroglial extracellular proteins is altered by growth environment. *Glia* 1989; 2:403-11

Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, Lippa C, Nixon RA. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain:evidence for early up-regulation of the endosomal-lysosomal system. *Neuron* 1995; 14:671-80

Quarless SA., Wells CN. Bochdalek hernia, incidental finding on sestamibi parathyroid scan. *Clin Nucl Med* 2005;30:436-439

James B, Chandler NC, and Quarless SA. Extrasosseous uptake of Tc-99m along the radiation therapy port for recurrent squamous cell carcinoma of the lung. *Clin Nucl Med* 2005;30:555-7

Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY and Wahl RL. Stunning and its effect on FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy treatment. *J. Nucl. Med.* 2006; 47:603-8

PRESENTATIONS:

Quarless SA., Wahl RL. The Effect of Chemotherapy Agents on the Expression of mRNA for Glucose Transporter-1 and Hexokinase Type-II: An in vitro Evaluation. Society of Nuclear Medicine, 50th Annual Meeting, June 21-25, 2003, New Orleans, LA

ABSTRACTS:

Quarless SA., Wahl RL. The Effect of Chemotherapy Agents on the Expression of mRNA for Glucose Transporter-1 and Hexokinase Type-II: An in vitro Evaluation. *J. Nucl. Med.* 2003; 44(suppl) :80P, 259

The American Board of Nuclear Medicine

Incorporated 1971

Certifies that


Shelley Ann Quarless

*has met the requirements of this Board and is qualified
during the period of 2001 through 2011 to practice as a Specialist
in all aspects of Clinical and Laboratory*

Nuclear Medicine

*including but not limited to Radiobioassay, Nuclear Imaging,
In Vivo Measurements & Therapy with Unsealed Radionuclides*

Ronald L. Nestor
Chairman



07192
Number JS


Richard J. Huspen
Secretary-Treasurer

New Jersey State Board of Medical Examiners
Division of Professional Regulation


THIS IS THE STATE BOARD OF MEDICAL EXAMINERS

HAS REGISTERED

Shelley A. [REDACTED]



FOR PRACTICE IN NEW JERSEY AS A Doctor of Podiatry




05/18/2007 TO 06/30/2009
VALID

25M607992700

Shelley A. [REDACTED]
Signature of Licensee/Registration Holder

[Signature]
Signature of Director

PERSONAL INFORMATION WAS REMOVED
BY NRC. NO COPY OF THIS INFORMATION
WAS RETAINED BY THE NRC.



The American Board of Nuclear Medicine

A Member Board of the American Board
of Medical Specialties

Chairman
Ronald L. Van Heertum, M.D.
New York, New York

Vice Chairman
Andrew T. Taylor, M.D.
Atlanta, Georgia

Secretary-Treasurer
Martin L. Narynowitz, M.D.
Galveston, Texas

Directors
Robert F. Carrota, M.D.
Roseville, California

Michael M. Graham, M.D.
Iowa City, Iowa

Lawrence E. Holder, M.D.
Baltimore, Maryland

Alan H. Mauer, M.D.
Philadelphia, Pennsylvania

Tom R. Miller, M.D., Ph.D.
St. Louis, Missouri

Christopher J. Palestro, M.D.
New Hyde Park, New York

David C. Price, M.D.
San Francisco, California

Edward B. Silberstein, M.D.
Cincinnati, Ohio

S. Ted Treves, M.D.
Boston, Massachusetts

Executive Director
William H. Blahd, M.D.
Los Angeles, California

Associate Executive Director
Heinrich R. Schelbert, M.D.
Los Angeles, California

Administrator
Gloria W. Gordon, M.P.H.
Los Angeles, California

Assistant Administrator
Gregory S. Vaughn, M.P.H.
Los Angeles, California

Please Address All
Communication To:

900 Veteran Avenue
Los Angeles, CA 90024-1786
Telephone (310) 825-6787
Fax (310) 794-4821

October 10, 2001

7192
QUARLESS, SHELLEY ANN

Dear Doctor:

With great pleasure the American Board of Nuclear Medicine informs you that you have passed its September 8, 2001 certifying examination in the broad field of nuclear medicine and are now recognized as a certified specialist in nuclear medicine. A certificate indicating this recognition will be sent to you in the near future. The American Board of Nuclear Medicine congratulates you upon your achievement and this recognition.

The scores below indicate your performance in the nine content areas of the certification examination. Your percent correct score and the percent correct score for all candidates is shown. This provides the opportunity to compare your performance with all candidates in 2001. The Board hopes this information will be useful to you.


Content Area	Percent Answered Correctly	Mean % Correct For All Takers
Bas.Sci./Rad.Hlth-NMR	53	62
Cardiovascular	63	65
Endocrine	67	60
Gastrointestinal	71	70
Hematology/Oncology	70	65
Neurology	65	65
Pulmonary	52	67
Renal	56	66
Musculo-skeletal	59	65

Very sincerely yours,

Ronald L. Van Heertum, MD
Chairman

The Johns Hopkins Hospital
Baltimore  Maryland

This certifies that
Shelley Ann Quarless, D.O.
has served on the Resident Staff
of The Johns Hopkins Hospital as
Assistant Resident, Resident on the
Radiology and Nuclear Medicine Service
from July 1, 2000 to June 30, 2002



Richard Wolf

CHIEF OF SERVICE

Ronald R. Peter

PRESIDENT

Henry D. Baker, Jr.

CHAIRMAN, BOARD OF TRUSTEES

**Tripler Army Medical Center
Health Physics Office
Fax: (808) 433 2440**

Fax

To: ATTN Dr. MUSTSA **From:** SSG John Irace
Phone: **Phone:**
Fax: **Pages:** 6, including cover sheet
Date: **CC:**
Re:

Urgent For Review Please Comment Please Reply Please Recycle

● Comments:

Authorization documents citing Dr. Shelly Quarless as Authorized User.

Included; 3 separate documents. 1 adding her to list of authorized user, 1 deleting, and 1 as a user.



August 8, 2008

POC is Mr. Michael A. Diodato, Security Specialist at (808) 433-1418

AUTHORIZATION TO USE RADIOACTIVE MATERIALS

(For use of this form refer to TAMC Reg 40-37)

Date: 5 October 2005

**THRU: Radiation Safety Officer
Health Physics Section
Tripler Army Medical Center**

**FROM: (Principal User and Organization)
Jerry M. Brown, COL., MC (1,2,3)
Nuclear Medicine Service
Tripler Army Medical Center**

**TO: Radiation Safety Committee
Tripler Army Medical Center**

Ph: 433-6583

Fax: 433-6255

List of Authorized/Supervised Users

Authorized Users

Breitwieser, James (1, 2)
Delaplain, Calvin B. (1, 2, 3)
Quarless, Shelley Ann (1,2,3)
 Prager, Douglas A. (1,2,3)
 Garcia-Pena, Edna
 Click, Michael E. (1, 2)

Supervised Users

Akau, Bryan
 Ashcraft, James
 Frew, Robert J.
 Gonzalez, Javier
 Kawaoka, Edward
 Rushing, Michael S.
 Towne, David B.
 Williams, John

Authorization Conditions

Human Use: Diagnostic and Therapeutic Use in Patients

- (1) Use of unsealed byproduct material for uptake, dilution, and excretion studies IAW 10 CFR 35.100.
- (2) Use of unsealed byproduct material for imaging and localization studies IAW 10 CFR 35.200.
- (3) Use of unsealed byproduct material for therapeutic administration IAW 10 CFR 35.300.

Human Use

Non-Human Use

Maximum Activity (of each radioisotope.)

Unsealed

Carbon-14	1.0 mCi
Chromium-51	5.0 mCi
Cobalt-57	5.0 mCi
Cobalt-58	5.0 mCi
Fluorine-18	200 mCi
Gallium-67	50.0 mCi
Indium-111	50.0 mCi *
Indium-111	1.0 Ci **
Iodine-123	3.0 mCi
Iodine-125	250 uCi
Iodine-131	600 mCi
Molybdenum-99	6.0 Ci
Phosphorus-32	50.0 mCi
Samarium-153	200 mCi
Strontium-89	50 mCi
Technetium-99m	5.0 Ci
Thallium-201	75 mCi
Yttrium-90	100 mCi

Sealed Sources

Americium-241	15.0 mCi
Barium-133	1.0 mCi
Cesium-137	30 60 mCi ***
Cesium-137	1.0 mCi
Cobalt-57	50 mCi
Cobalt-60	1.0 mCi
Europium-152	0.5 uCi ****
Gadolinium-153	600 mCi
Germanium-68	50.0 mCi
Radium-226	5.0 uCi mg
Strontium-90	25 mCi

*For imaging, localization, uptake, dilution and excretion studies.

**For therapeutic use.

***Maximum activity per source is 30 mCi (NRC License Item #N6H).

****The maximum amount per housing is 300 mCi.

Radioactive Material Use Areas

NMS Rooms: Pharmacy (3A-104), Wash Sink (3A104), Dose Room (3A-105), Triple Head Spect Picker 3000 (3A-151), Uptake Probe (3A-153), Bone Density QDR4500A (3A-157), Body Scanner SIEMENS (3A-159), Picker 2000 (3A-161), Argus ADAC Single Head (3A160), ADAC Single Head ARGUS (3A-158), VERTEX ADAC (3A-156), Treadmill Room (4A102A)

Radioactive Material Storage Areas

Pharmacy (3A-104), Storage Rm (3A-102), Siemens Body Scan (3A-159), ADAC VERTEX (3A-156), Dose Room (3A-105), Storage Rm (3A-005)

AUTHORIZATION TO USE RADIOACTIVE MATERIALS

(For use of this form refer to TAMC Reg 40-37)

Date: 08 July 2004

THRU: Radiation Safety Officer
Health Physics Section
Tripler Army Medical Center

FROM: (Principal User and Organization)
Nuclear Medicine Service
Tripler Army Medical Center

TO: Radiation Safety Committee,
Tripler Army Medical Center

PH 432-6586

FAX: 432-6285

List of Authorized/Supervised Users

Authorized Users

- Behari, Khrosow (1, 2, 3)
- Breitwieser, James (1, 2)
- Chick, Michael E. (1, 2)
- Delaplain, Calvin B. (1, 2, 3)
- Quonover, Stephen (1, 2, 3)
- Toney, Morakinyo A. O. (1, 2, 3)
- Garcia-Pena, Edna

Supervised Users

- Akua, Bryan
- Asheriff, James
- Brew, Robert J.
- Gonzalez, Javier
- Kawaoka, Edward
- Sandford, Angie A.
- Williams, John

Authorization Conditions:

- Human Use: Diagnostic and Therapeutic Use in Patients
- (1) Use of unsealed byproduct material for uptake, dilution, and excretion studies (AW 10 CFR 35.100)
- (2) Use of unsealed byproduct material for imaging and localization studies (AW 10 CFR 35.200)
- (3) Use of unsealed byproduct material for therapeutic administration (AW 10 CFR 35.300)

Human Use

Non-Human Use

Maximum Activity (of each radioisotope)

Unsealed

Carbon-14	10000
Chromium-51	10000
Chromium-52	50000
Cobalt-60	50000
Fluorine-18	20000
Gold-198	50000
Indium-111	50000
Iodine-125	10000
Iodine-131	10000
Iodine-129	10000
Iron-59	10000
Mercury-197	10000
Phosphorus-32	50000
Potassium-40	20000
Selenium-75	50000
Selenium-76	50000
Thallium-201	25000
Yttrium-90	10000

Sealed Sources

Americium-241	10000
Bismuth-213	10000
Cesium-137	70000
Cobalt-60	50000
Gold-198	10000
Europium-152	10000
Gold-197	10000
Germanium-68	20000
Radium-226	50000
Neutron-252	25000

* For unsealed sources, dilution and excretion studies.
 ** For diagnostic use.
 *** Maximum activity for personnel is 20 mCi.
 **** For maximum amount per housing is 700 mCi.

Radioactive Material Use Areas

NMS Room 3, Pharmacy (CA-104), Waste Sink (CA-104), Lab Room (CA-105), Trip's Head Space (CA-106), CA-107, Single Head (CA-108), Room Therapy (CA-109), CA-110, Body Scanner (CA-111), Printer (CA-112), CA-113, CA-114, Single Head (CA-115), CA-116, Single Head (CA-117), CA-118, ARVUS (CA-119), VERTEX (CA-120), CA-121, CA-122, CA-123, CA-124, CA-125, CA-126, CA-127, CA-128, CA-129, CA-130, CA-131, CA-132, CA-133, CA-134, CA-135, CA-136, CA-137, CA-138, CA-139, CA-140, CA-141, CA-142, CA-143, CA-144, CA-145, CA-146, CA-147, CA-148, CA-149, CA-150, CA-151, CA-152, CA-153, CA-154, CA-155, CA-156, CA-157, CA-158, CA-159, CA-160, CA-161, CA-162, CA-163, CA-164, CA-165, CA-166, CA-167, CA-168, CA-169, CA-170, CA-171, CA-172, CA-173, CA-174, CA-175, CA-176, CA-177, CA-178, CA-179, CA-180, CA-181, CA-182, CA-183, CA-184, CA-185, CA-186, CA-187, CA-188, CA-189, CA-190, CA-191, CA-192, CA-193, CA-194, CA-195, CA-196, CA-197, CA-198, CA-199, CA-200, CA-201, CA-202, CA-203, CA-204, CA-205, CA-206, CA-207, CA-208, CA-209, CA-210, CA-211, CA-212, CA-213, CA-214, CA-215, CA-216, CA-217, CA-218, CA-219, CA-220, CA-221, CA-222, CA-223, CA-224, CA-225, CA-226, CA-227, CA-228, CA-229, CA-230, CA-231, CA-232, CA-233, CA-234, CA-235, CA-236, CA-237, CA-238, CA-239, CA-240, CA-241, CA-242, CA-243, CA-244, CA-245, CA-246, CA-247, CA-248, CA-249, CA-250, CA-251, CA-252, CA-253, CA-254, CA-255, CA-256, CA-257, CA-258, CA-259, CA-260, CA-261, CA-262, CA-263, CA-264, CA-265, CA-266, CA-267, CA-268, CA-269, CA-270, CA-271, CA-272, CA-273, CA-274, CA-275, CA-276, CA-277, CA-278, CA-279, CA-280, CA-281, CA-282, CA-283, CA-284, CA-285, CA-286, CA-287, CA-288, CA-289, CA-290, CA-291, CA-292, CA-293, CA-294, CA-295, CA-296, CA-297, CA-298, CA-299, CA-300, CA-301, CA-302, CA-303, CA-304, CA-305, CA-306, CA-307, CA-308, CA-309, CA-310, CA-311, CA-312, CA-313, CA-314, CA-315, CA-316, CA-317, CA-318, CA-319, CA-320, CA-321, CA-322, CA-323, CA-324, CA-325, CA-326, CA-327, CA-328, CA-329, CA-330, CA-331, CA-332, CA-333, CA-334, CA-335, CA-336, CA-337, CA-338, CA-339, CA-340, CA-341, CA-342, CA-343, CA-344, CA-345, CA-346, CA-347, CA-348, CA-349, CA-350, CA-351, CA-352, CA-353, CA-354, CA-355, CA-356, CA-357, CA-358, CA-359, CA-360, CA-361, CA-362, CA-363, CA-364, CA-365, CA-366, CA-367, CA-368, CA-369, CA-370, CA-371, CA-372, CA-373, CA-374, CA-375, CA-376, CA-377, CA-378, CA-379, CA-380, CA-381, CA-382, CA-383, CA-384, CA-385, CA-386, CA-387, CA-388, CA-389, CA-390, CA-391, CA-392, CA-393, CA-394, CA-395, CA-396, CA-397, CA-398, CA-399, CA-400, CA-401, CA-402, CA-403, CA-404, CA-405, CA-406, CA-407, CA-408, CA-409, CA-410, CA-411, CA-412, CA-413, CA-414, CA-415, CA-416, CA-417, CA-418, CA-419, CA-420, CA-421, CA-422, CA-423, CA-424, CA-425, CA-426, CA-427, CA-428, CA-429, CA-430, CA-431, CA-432, CA-433, CA-434, CA-435, CA-436, CA-437, CA-438, CA-439, CA-440, CA-441, CA-442, CA-443, CA-444, CA-445, CA-446, CA-447, CA-448, CA-449, CA-450, CA-451, CA-452, CA-453, CA-454, CA-455, CA-456, CA-457, CA-458, CA-459, CA-460, CA-461, CA-462, CA-463, CA-464, CA-465, CA-466, CA-467, CA-468, CA-469, CA-470, CA-471, CA-472, CA-473, CA-474, CA-475, CA-476, CA-477, CA-478, CA-479, CA-480, CA-481, CA-482, CA-483, CA-484, CA-485, CA-486, CA-487, CA-488, CA-489, CA-490, CA-491, CA-492, CA-493, CA-494, CA-495, CA-496, CA-497, CA-498, CA-499, CA-500, CA-501, CA-502, CA-503, CA-504, CA-505, CA-506, CA-507, CA-508, CA-509, CA-510, CA-511, CA-512, CA-513, CA-514, CA-515, CA-516, CA-517, CA-518, CA-519, CA-520, CA-521, CA-522, CA-523, CA-524, CA-525, CA-526, CA-527, CA-528, CA-529, CA-530, CA-531, CA-532, CA-533, CA-534, CA-535, CA-536, CA-537, CA-538, CA-539, CA-540, CA-541, CA-542, CA-543, CA-544, CA-545, CA-546, CA-547, CA-548, CA-549, CA-550, CA-551, CA-552, CA-553, CA-554, CA-555, CA-556, CA-557, CA-558, CA-559, CA-560, CA-561, CA-562, CA-563, CA-564, CA-565, CA-566, CA-567, CA-568, CA-569, CA-570, CA-571, CA-572, CA-573, CA-574, CA-575, CA-576, CA-577, CA-578, CA-579, CA-580, CA-581, CA-582, CA-583, CA-584, CA-585, CA-586, CA-587, CA-588, CA-589, CA-590, CA-591, CA-592, CA-593, CA-594, CA-595, CA-596, CA-597, CA-598, CA-599, CA-600, CA-601, CA-602, CA-603, CA-604, CA-605, CA-606, CA-607, CA-608, CA-609, CA-610, CA-611, CA-612, CA-613, CA-614, CA-615, CA-616, CA-617, CA-618, CA-619, CA-620, CA-621, CA-622, CA-623, CA-624, CA-625, CA-626, CA-627, CA-628, CA-629, CA-630, CA-631, CA-632, CA-633, CA-634, CA-635, CA-636, CA-637, CA-638, CA-639, CA-640, CA-641, CA-642, CA-643, CA-644, CA-645, CA-646, CA-647, CA-648, CA-649, CA-650, CA-651, CA-652, CA-653, CA-654, CA-655, CA-656, CA-657, CA-658, CA-659, CA-660, CA-661, CA-662, CA-663, CA-664, CA-665, CA-666, CA-667, CA-668, CA-669, CA-670, CA-671, CA-672, CA-673, CA-674, CA-675, CA-676, CA-677, CA-678, CA-679, CA-680, CA-681, CA-682, CA-683, CA-684, CA-685, CA-686, CA-687, CA-688, CA-689, CA-690, CA-691, CA-692, CA-693, CA-694, CA-695, CA-696, CA-697, CA-698, CA-699, CA-700, CA-701, CA-702, CA-703, CA-704, CA-705, CA-706, CA-707, CA-708, CA-709, CA-710, CA-711, CA-712, CA-713, CA-714, CA-715, CA-716, CA-717, CA-718, CA-719, CA-720, CA-721, CA-722, CA-723, CA-724, CA-725, CA-726, CA-727, CA-728, CA-729, CA-730, CA-731, CA-732, CA-733, CA-734, CA-735, CA-736, CA-737, CA-738, CA-739, CA-740, CA-741, CA-742, CA-743, CA-744, CA-745, CA-746, CA-747, CA-748, CA-749, CA-750, CA-751, CA-752, CA-753, CA-754, CA-755, CA-756, CA-757, CA-758, CA-759, CA-760, CA-761, CA-762, CA-763, CA-764, CA-765, CA-766, CA-767, CA-768, CA-769, CA-770, CA-771, CA-772, CA-773, CA-774, CA-775, CA-776, CA-777, CA-778, CA-779, CA-780, CA-781, CA-782, CA-783, CA-784, CA-785, CA-786, CA-787, CA-788, CA-789, CA-790, CA-791, CA-792, CA-793, CA-794, CA-795, CA-796, CA-797, CA-798, CA-799, CA-800, CA-801, CA-802, CA-803, CA-804, CA-805, CA-806, CA-807, CA-808, CA-809, CA-810, CA-811, CA-812, CA-813, CA-814, CA-815, CA-816, CA-817, CA-818, CA-819, CA-820, CA-821, CA-822, CA-823, CA-824, CA-825, CA-826, CA-827, CA-828, CA-829, CA-830, CA-831, CA-832, CA-833, CA-834, CA-835, CA-836, CA-837, CA-838, CA-839, CA-840, CA-841, CA-842, CA-843, CA-844, CA-845, CA-846, CA-847, CA-848, CA-849, CA-850, CA-851, CA-852, CA-853, CA-854, CA-855, CA-856, CA-857, CA-858, CA-859, CA-860, CA-861, CA-862, CA-863, CA-864, CA-865, CA-866, CA-867, CA-868, CA-869, CA-870, CA-871, CA-872, CA-873, CA-874, CA-875, CA-876, CA-877, CA-878, CA-879, CA-880, CA-881, CA-882, CA-883, CA-884, CA-885, CA-886, CA-887, CA-888, CA-889, CA-890, CA-891, CA-892, CA-893, CA-894, CA-895, CA-896, CA-897, CA-898, CA-899, CA-900, CA-901, CA-902, CA-903, CA-904, CA-905, CA-906, CA-907, CA-908, CA-909, CA-910, CA-911, CA-912, CA-913, CA-914, CA-915, CA-916, CA-917, CA-918, CA-919, CA-920, CA-921, CA-922, CA-923, CA-924, CA-925, CA-926, CA-927, CA-928, CA-929, CA-930, CA-931, CA-932, CA-933, CA-934, CA-935, CA-936, CA-937, CA-938, CA-939, CA-940, CA-941, CA-942, CA-943, CA-944, CA-945, CA-946, CA-947, CA-948, CA-949, CA-950, CA-951, CA-952, CA-953, CA-954, CA-955, CA-956, CA-957, CA-958, CA-959, CA-960, CA-961, CA-962, CA-963, CA-964, CA-965, CA-966, CA-967, CA-968, CA-969, CA-970, CA-971, CA-972, CA-973, CA-974, CA-975, CA-976, CA-977, CA-978, CA-979, CA-980, CA-981, CA-982, CA-983, CA-984, CA-985, CA-986, CA-987, CA-988, CA-989, CA-990, CA-991, CA-992, CA-993, CA-994, CA-995, CA-996, CA-997, CA-998, CA-999, CA-1000.

Radioactive Material Storage Areas

Pharmacy (CA-104), Storage Room (CA-105), Storage Room (CA-106), VLM (CA-107), Lab Room (CA-108), Storage Room (CA-109).

Conditions of Use (Use additional sheets where necessary)

- (1) **Inspection**
 - (a) Inspections shall be performed some time between 12 hours of assembly of each incoming radiopharmaceutical container.
 - (b) Quarterly inspections shall be performed for all the workers as specified in TAMC REG, 416.17.
- (2) **Use of Labels**
 - (a) Labels on the Use of Containers will be done in accordance with the model procedure contained in NRC Regulatory Guide 1.107, NRC Regulatory Guide 1.108, Appendix C.
- (3) **ALARA**
 - (a) ALARA responsibility shall be maintained by the laboratory technician via a program of individual efficiency entering the tower system on a daily basis.
 - (b) The time spent in radioactive material shall under the tower system through approval of weeks per month.
 - (c) Average empty quarterly remains one percent of the initial activity.
- (4) **Ordering**
 - (a) An NRC Subject shall be obtained prior to ordering any radionuclides.
 - (b) Ordering of radiopharmaceuticals shall be limited to radionuclides specified in this order and shall be in accordance with NRC Reg Guide 1.108, Appendix C.
- (5) **Package Receipt** - Package receipt will be in accordance with NRC Reg Guide 1.103, Appendixes K and L.
- (6) **Preparation and administration of QM radiopharmaceuticals** - Preparation of radiopharmaceuticals will be done in accordance with the direct involvement of the authorized Nuclear Pharmacist, or Mr. Bryan Akam, or Mr. Brian Kawaska, and a qualified Nuclear Medicine Physician.
- (7) **Shipping** - Shipping of radioactive materials is not authorized.
- (8) **Temporary Supervised User Authorizations**
 - (a) Pharmacy students and radiology residents approved by the TAMC HPS are temporarily authorized to work as "supervised users" for a period not to exceed one continuous month.
 - (b) Residents and students are not allowed to work as "supervised users" until they have received the appropriate radiation safety training and competency device from the TAMC HPS.
- (9) **Supervision** - The degree of supervision of a "supervised user" by an "authorized user" shall be commensurate with the experience and training of the "supervised user".

Revision Summary





List of Authorized/Supervised Users: Change Peter Paulson, MAJ, MS to KYLE L. MC, MAJ, MS
 Change Supervised User name Jacqueline L. Dowd to Jacqueline L. Johnson

Maximum Activity:

Radioactive Material Use Areas:

Radioactive Material Storage Areas:

Conditions of Use:

Acknowledgement of responsibilities:	
 SHELLY ANN QUARLESS, MAJ, MC Principal User	 JAMES A. BREITWESER, COL, MC Administrative Official
Approved:  ARTHUR R. MORTON, MAJ, MS Radiation Safety Officer	Approved:  BERRY, KEVIN G., CAPT, MC, USN RSC Chairperson
Authorization No. F78 NCA Expires 11 SEP 06	

REQUEST FOR USE OF RADIOACTIVE MATERIALS

Date: 29 OCT 02

(For use of this form refer to TAMC Reg 40-37)

THRU: Radiation Safety Officer
 Health Physics Office
 Tripler Army Medical Center

FROM: (Principle User and Organization)
 Sun Y. Kim (1, 2, 3)
 Nuclear Medicine Service
 Tripler Army Medical Center

TO: Radiation Safety Committee
 Tripler Army Medical Center

Ph: 433-6583

Fax: 433-6255

List all Co-Workers and Organizations

Authorized Users

Behjati, Khrosrow (1, 2, 3)
 Bretwaser, James (1, 2)
 Carvalho, Joseph (1, 2, 3)
 Click, Michael E. (1, 2)
 Delaplain, Calvin B. (1, 2, 3)
 Quarless, Shelley Ann (1, 2)
 Toney, Morakinyo A. O. (1, 2, 3)
 Durkin, Robert J

Supervised Users

Akau, Bryan
 Gonzalez, Javier
 Graham, Richard J.
 Kawaoka, Edward
 Noboa, Leonard
 Sanford, Angie A.
 Shultz, Robert D
 Williams, John

Authorization Conditions

Human Use: Diagnostic and Therapeutic Use in Patients

- (1) Use of unsealed byproduct material for uptake, dilution, and excretion studies IAW 10 CFR 35.100.
- (2) Use of unsealed byproduct material for imaging and localization studies IAW 10 CFR 35.200.
- (3) Use of unsealed byproduct material for therapeutic administration IAW 10 CFR 35.300.

Radionuclides and maximum Activity of each which may be possessed at any one time

<input checked="" type="checkbox"/> Unsealed	
Carbon-14	1.0 mCi
Chromium-51	5.0 mCi
Cobalt-57	5.0 mCi
Cobalt-58	5.0 mCi
Fluorine-18	200 mCi
Gallium-67	50.0 mCi
Indium-111	**50.0 mCi
Iodine-123	3.0 mCi
Iodine-125	250 uCi
Iodine-131	*600 mCi
Molybdenum-99	6.0 Ci
Phosphorus-32	50.0 mCi
Samarium-153	200 mCi
Strontium-89	50 mCi
Technetium-99m	5.0 Ci
Thallium-201	75 mCi
Yttrium-90	200 mCi +00-mCi

<input checked="" type="checkbox"/> Sealed Sources	
Americium-241	15.0 mCi
Barium-133	1.0 mCi
Cesium-137	*70 mCi
Cobalt-57	50 mCi
Cobalt-60	1.0 mCi
Europium-152	0.5 uCi
Gadolinium-153	***600 mCi
Germanium-68	50.0 mCi
Radium-226	5.0 uCi
Strontium-90	25 mCi

*Maximum activity per source is 30 mCi.

**The maximum amount for imaging or localization studies is 50 mCi, the maximum amount for radiopharmaceutical therapy is 1.0 Ci.

***The maximum amount per housing is 300 mCi.

Areas of Radioactive Material Use

NMS Rooms: Pharmacy (3A-104), Wash Sink (3A104), Dose Room (3A-105), Triple Head Spect Picker 3000 (3A-151), Intake Probe (3A-153), Portable General Electric (3A-155), Bone Density QDR4500A (3A-157), Body Scanner SIEMENS (3A-159), Picker 2000 (3A-161), Xe Room Argus ADAC Single Head 3A160, ADAC Single Head ARGUS (3A-158), VERTEX ADAC (3A-156), Treadmill Room (4A102A)

Human Use

Location of Radioactive Material Storage

Pharmacy (3A-104), Storage Rm (3A-102), Siemens Body Scan (3A-150), ADAC VERTEX (3A-156), Dose Room (3A-105), Storage Rm (3A-005)

Non-Human Use

Description of Use (Use additional sheets where necessary; list references and show dose calculations where applicable, disposal, counting or assay procedures)

Authorization Conditions

Non- Human Use: Calibration and Testing of Equipment

(1) Bioassays

- (a) Bioassays shall be performed some time between 6-72 hours of assaying or administering radiopharmaceutical doses
- (b) Quarterly bioassays shall be performed for all rad workers as specified in TAMC REG 40-37 Chapter 6-4.n.(1)(a).

(2) Dose Calibrator - Calibrations of the Dose Calibrators will be done in accordance with the model procedure contained in NRC Regulatory Guide 10.2 NRC Regulatory Guide 10.8 Appendix C.

(3) Sink

- (a) A disposal log shall be maintained by the laboratory to document the amount of radioactive effluent entering the sewer system on a daily basis.
- (b) Less than 1.0 mCi radioactive material shall enter the sewer system through approved sinks per month.
- (c) Assume empty glassware contains one percent of the initial activity.

(4) Ordering

- (a) Ordering of radiopharmaceuticals shall be limited to radioisotopes specified in this authorization, and in accordance with NRC Reg Guide 10.8, Appendix K.
- (b) An HPO Number shall be obtained prior to ordering any isotopes.

(5) Package Receipt - Package receipt will be in accordance with NRC Reg Guide 10.8, Appendices K and L.

(6) Preparation and administration of OMP radiopharmaceuticals - Therapeutic radiopharmaceuticals will be drawn or administered with the direct involvement of the authorized Nuclear Pharmacist, or Mr. Bryan Akau, or Mr. Edward Kawaoka, and a qualified Nuclear Medicine Physician.

(7) Shipping - Shipping of radioactive materials is not authorized.

(8) Temporary Supervised User Authorizations

- (a) Pharmacy residents/students and radiology residents approved by the TAMC HPS are temporarily authorized to work as "supervised users" for a period not to exceed two consecutive months.
- (b) Residents and students are not allowed to work as "supervised users" until they have received the appropriate radiation safety training and dosimetry devices from the TAMC HPS.

(9) Supervision - The degree of supervision of a "supervised user" by an "authorized user" shall be commensurate with the experience and training of the "supervised user".

Revision Descriptions

The conditions of the previous authorization are still applicable with the following revisions:

Principle User:
Authorized Users: ADD: Quarless, Shelley Ann
Supervised Users: ADD: Sanford, Angie A.

Maximum Activity: **Radioactive Material Use Areas:**
Radioactive Storage Area:
Description of use:

I acknowledge my responsibilities as Principle User:


 SUN Y. KIM, LTC, MC

Signature

Administrative Approval:


 JAMES A. BREITWESER, COL, MC

Signature

TAMC RADIATION SAFETY COMMITTEE APPROVAL

APPROVED:


 ARTHUR R. MORTON, MAJ, MS

Radiation Safety Officer

APPROVED:


 RICHARD R. JEFFRIES, CAPT, MC, USN

RSC Chairperson

Authorization No.

F76.N01

Expires

30-Oct-03

This is to acknowledge the receipt of your letter/application dated

8/20/08, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment (29-3119-01) There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 142741.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader